ChristopherJHoimesDO

Genitourinary Oncology

Associate Professor of Medicine-Bladder/Renal and GU Oncology at Duke University

Dr. Hoimes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Christopher Hoimes, DO, is an oncology specialist with a focus on genitourinary oncology, based in Durham, NC. He completed fellowships in hematology and medical oncology and genitourinary oncology at Yale-New Haven Medical Center and Hospital, and his residency in internal medicine at Penn State Milton S Hershey Medical Center. Currently, he serves as a physician at Duke University Medical Center and as a hematologist/oncologist at University Hospitals Seidman Cancer Center. He holds an academic role as an assistant professor at Case Western Reserve University School of Medicine. His expertise includes immunotherapy and various cancers including renal cell carcinoma. Dr. Hoimes has published research on genomic biomarkers and immune checkpoint inhibitors and is involved in clinical trials for treatments of urothelial and bladder cancer.

Yale School of MedicinePost-Doctoral Fellowship, 2008 - 2012
Yale-New Haven HospitalFellowship, Genitourinary Oncology, 2009 - 2010
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Penn State Milton S Hershey Medical CenterChief Residency, Internal Medicine, 2005 - 2006
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2002 - 2005
NYIT College Of Osteopathic MedicineClass of 2001

PubMed

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen
European Urology Oncology. 2024-12-20
Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors.
Dheeman Futela, Sree Harsha Tirumani, Ezgi Guler, Brandon Declouette, Christopher Hoimes
Current Problems in Diagnostic Radiology. 2024-12-10
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors.
Christopher J Hoimes, Suzanne McGettigan, Lee Schwartzberg
The American Journal of Medicine. 2024-12-01

Books/Book Chapters

Cancer: Principles and Practice of Oncology
Chapter: Antimicrotuble Agents
Christopher J Hoimes and L. HarrisEditors: DeVita, Hellman, Rosenberg.Edition 10th,2015
Essentials and Updates in Urologic Oncology
Chapter: Systemic Therapy for Advanced Prostate Cancer
Christopher J Hoimes, G. Gibney, W.M. KellyEditors: Philippe E. Spiess.2013

Lectures

EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
2019 ASCO Annual Meeting - 6/1/2019

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder CancerSeptember 28th, 2019